Market Signal Briefing

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

The Campbell’s Company (NASDAQ: CPB) will begin 2026 with a fresh dividend payout to shareholders, continuing its long-running policy of steady quarterly distributions.

According to the company’s latest declaration, investors of record on January 8, 2026, will receive a dividend of $0.39 per share, payable on February 2, 2026. For anyone holding 100 shares of CPB, the upcoming payment will amount to $39. 

The new distribution maintains the dividend level the company has kept throughout 2025. Campbell’s paid the same amount on August 4, 2025, followed by another $0.39 payment on November 3, 2025. 

Campbell’s Company dividend schedule. Source: Campbell’s.
With the February 2026 payout now scheduled, the company is on track to continue its consistent quarterly pattern at a time when investors are paying close attention to its financial stability.

CPB stock fundamentals 
The steady dividend arrives during a turbulent period for the stock. As reported by Finbold, Campbell’s was thrust into controversy after an audio recording surfaced in which senior executive Martin Bally, a vice president in the IT division, made disparaging remarks about the company’s customers and products.

In the recording, he referred to Campbell’s foods as being “for poor people,” mocked consumers, and mentioned “3D-printed chicken” in a way that raised questions about product integrity.

The recording also captured offensive comments about Indian colleagues. Once the company verified the voice, Bally was placed on leave and ultimately terminated.

The episode drew legal scrutiny, triggered a lawsuit, and led to negative headlines that pressured the stock. Shares fell more than 3% during one trading session following the reports, adding instability to a stock already navigating a difficult operating environment. As of press time, CPB stock was trading at $30 having dropped over 2% in the past week. 

CPB one-week stock price chart. Source: Google Finance.
The controversy comes on top of broader financial concerns. Campbell’s most recent fiscal results showed only slight revenue growth, and its outlook for fiscal 2026 included the possibility of lower adjusted earnings.

Management has expanded its cost-savings target to $375 million by 2028 in an effort to protect margins. Even so, the combination of weak organic sales trends and reputational issues has weighed on market confidence.

Featured image via Shutterstock

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

November 30, 2025 7:45 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - November 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued For Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company's older devices.

Why did Inspire's Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an "elongated timeframe" and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers "did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V," that certain "software updates for claims submissions and processing did not take effect until July 1, [2025]" which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire's customers had a backlog of older versions of the company's device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275915

November 30, 2025 7:46 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - November 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

Investors have until January 2, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities. The case is pending in the U.S. District Court for the District of Maryland and is captioned Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602.

Why is CarMax Being Sued For Securities Fraud?

CarMax sells used cars. During the relevant period, the Company touted the strong and sustainable demand for its cars, driven by factors such as a seamless customer experience.

As alleged, in truth, it appears that the announcement of U.S. tariffs imposed on cars provided a short-term boost to demand, as customers purchased cars prior to the tariffs taking effect.

BFA Law is also investigating the unexpected departure of CEO Bill Nash on November 6, 2025, and whether CarMax properly assessed or reserved for its portfolio of car loans.

Why did CarMax's Stock Drop?

On September 25, 2025, the Company reported disappointing financial results for the second quarter of its fiscal year 2026. Specifically, CarMax announced sales declines across the board, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units. The Company also posted a disappointing second quarter net income of about $95.4 million, down from $132.8 million over the prior year. A main reason for the declines, according to CarMax, was a "pull forward" in demand into the first fiscal quarter due to the announcement of tariffs.

On this news, the price of CarMax stock dropped $11.45 per share, or roughly 20%, from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025.

Then, on November 6, 2025, CarMax announced the unexpected departure of CEO Bill Nash and a weak preliminary Q3 2025 outlook. On this news, the price of CarMax stock dropped over 24%.

Click here for more information: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

What Can You Do?

If you invested in CarMax you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275918

November 30, 2025 7:46 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - November 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

Investors have until December 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410.

Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company's Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company's fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers "rely on Synopsys IP to minimize integration risk and speed time to market" and that it was seeing "strength in Europe and South Korea." Synopsys also stated it was "continuing to develop and deploy[] AI into our products and the operations of our business."

As alleged, in truth, the Company's Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

The Stock Declines as the Truth Is Revealed

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its "IP business underperformed expectations." The Company reported revenue for its Design IP segment of $425.9 million, a 7.7% decline year-over-year and net income of $242.5 million, a 43% year-over-year decline. The Company revealed that its Design IP customers require "more and more customization," which "takes longer" and requires "more resources." As a result, the Company stated it was having "an ongoing dialogue with our customers" regarding changing its business model. This news caused the price of Synopsys stock to fall $217.59 per share, or nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025.

Click here for more information: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

What Can You Do?

If you invested in Synopsys you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275921

CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company is announcing new offerings and major enhancements across its portfolio, spanning disease detection, assessment and monitoring, remote scanning, image management and interpretation, center operations and AI orchestration—all designed to transform the imaging experience and advance population health.

“We are entering an era where AI-powered imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “At DeepHealth, we harness AI in an integrated, end-to-end approach across our portfolio with the intent to improve healthcare delivery. By unifying clinical and operational intelligence into DeepHealth OS and deploying scalable infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency. This is how we advance our mission of empowering breakthroughs in care through imaging.”

At RSNA this year, DeepHealth showcases an expanded, integrated portfolio of AI-powered solutions that demonstrate real-world impact in addressing key healthcare challenges such as disconnected patient engagement, strained workforce, inconsistent clinical outcomes and technology, data and workflow fragmentation. 

Unifying the Imaging Experience 
DeepHealth connects siloed tools, teams, and workflows to automate and orchestrate key tasks in the end-to-end imaging experience. DeepHealth showcases these solutions at RSNA through its enterprise imaging and operations portfolio that includes: 

Diagnostic Suite™1 — Accelerating and Automating Radiology: DeepHealth’s cloud-first enterprise image management and interpretation solutions deliver capabilities to automate and accelerate radiology at scale. New functionalities include cloud and hybrid data management with rapid migration, scalable ultra-fast streaming diagnostic viewer, AI-powered automated reporting and integrated advanced visualization, and enterprise AI orchestration in one seamless diagnostic environment. The recent acquisition of CIMAR UK brings additional advanced cloud image management and interoperability capabilities, supporting expanded deployments across the UK and Europe to accelerate AI-powered imaging, reporting and image-based screening. Components of Diagnostic Suite are actively deployed across RadNet sites and other customers, reflecting the Suite’s ability to deliver impact at scale in both outpatient and teleradiology environments. 
TechLive™ — Expanding Capacity and Access: TechLive is a multimodality, vendor-agnostic remote imaging and radiology management solution. With first-of-kind 510(k) clearance, it extends expert oversight across MR, Ultrasound, CT and PET/CT to accelerate onboarding, meet diverse workforce needs and expand access to advanced imaging.2 Deployment at RadNet to date has connected more than 400 scanners to TechLive, with results showing 42% fewer MR room closures, driving higher throughput and better patient and technologist experiences.2 TechLive is available as a standalone solution or through an expanded collaboration with GE HealthCare for use with its ultrasound products. In addition, TechLive can be combined with Alpha RT as remote-scanning technology with staffing and training expertise to support diverse workforce and operational needs. 
Operations Suite™ — Intelligent, Connected Imaging Operations: DeepHealth’s Operations Suite is an expanded, cloud-first suite of solutions that unifies scheduling, registration, billing, analytics and patient communication into a single environment. The Suite introduces new Patient Engagement solutions designed to improve communication, scheduling and adherence, along with agentic AI capabilities that enable automation to reduce administrative burden, optimize throughput and improve system-wide coordination. Operations Suite is being deployed across RadNet and other customer sites, as recently announced. Current customers leveraging DeepHealth RIS, previously eRAD RIS, will have the option to transition to Operations Suite through updated functionalities. 
Advancing Population Health with Clinical AI Solutions 
DeepHealth is introducing major advancements across its Population Health & Clinical AI portfolio, supported by expanded and new FDA clearances across multiple clinical areas. These innovations are designed to help stage shift disease, drive more timely and effective screening and diagnostic pathways, and expand patient access: 

DeepHealth Breast Suite — Elevating Breast Cancer Detection and Diagnosis: The new Breast Suite3 an AI-powered, FDA-cleared end-to-end suite of modular interoperable applications that significantly enhances diagnostic accuracy,4 improve workflow efficiency and drive greater standardization of care.4,5 Breast Suite delivers one of the industry’s most comprehensive breast cancer detection and diagnostic offerings by including breast cancer detection, risk asssesment,6 breast density, workflow tools and, in development, breast arterial calcification assessment.7 Breast Suite builds on organic innovation and technology integrated through the acquisition of iCAD to deliver a comprehensive new suite of solutions. Breast Suite applications already support annually more than 10 million mammograms globally.The largest real-world analysis of AI-powered breast cancer screening in the US recently published in Nature Health demonstrated the effectiveness of applications within Breast Suite to deliver a 21% increase in breast cancer detection rate in over 579,000 women, with consistent benefits across dense-breast and diverse patient populations.4DeepHealth and GE HealthCare will expand their existing collaboration to include a wider suite of AI tools and extend access to the combined offering of their mammography systems with DeepHealth Breast Suite worldwide. DeepHealth Thyroid Suite — Transforming Thyroid Ultrasound Imaging: The Thyroid Suite,8 an AI-powered suite of modular applications seamlessly integrates into existing thyroid ultrasound workflows and technology, automating measurements and characterization9,10 and significantly improving workflow efficiency.11 By automating nodule detection, characterization and standardizing worksheets and reporting, Thyroid Suite applications help radiologists and sonographers work more efficiently and consistently. Thyroid Suite builds on organic innovation and technology integrated through the acquisition of See-Mode to deliver a new suite of solutions. Deployment across more than 200 sites within RadNet has demonstrated transformative real-world impact: radiologists interpreting more than 4,070 nodules accepted AI-based measurements and characterization without correction in greater than 94% of the cases.12 The solution supports all ultrasound manufacturers and is available standalone or through the recently announced partnership with GE HealthCare’s ultrasound imaging.DeepHealth Neuro Suite — Quantifying Structural Changes for Proactive Care: The Neuro Suite13 applications automate and standardize neuroimaging analysis. It includes the FDA-cleared applications: Brain Health for white matter hyperintensity (WMH) detection and segmentation and Brain Age for volumetric measurement. By automatically quantifying key structures — including the hippocampus, lobes and subcortical regions — Neuro Suite tracks longitudinal progression to support proactive care.DeepHealth Chest Suite — Stage Shifting Lung Cancer: The applications of the expanded Chest Suite,14 previously referred to as DeepHealth Lung, automate pulmonary nodule detection, characterization and volumetric quantification, as well as standardize reporting and longitudinal tracking. These automations support radiologists in identifying disease earlier and improving diagnostic accuracy,15,16 Chest Suite applications continue to enable population-scale screening programs worldwide, including NHS England’s Lung Cancer Screening Program for which UK Government data show that 76% of detected cancers are now caught at earlier, more treatable stages, compared to only 29% historically.17 Applications within the Chest Suite are cleared in Europe and the UK and are currently US 510(k)-pending, with plans to expand availability to US clinical sites. DeepHealth Prostate Suite — Advancing Diagnosis of Prostate Cancer: The next generation Prostate Suite18 streamlines prostate MRI interpretation, analysis and biopsy planning workflows. The suite integrates automated lesion detection and risk classification (510K pending), intelligent gland segmentation with PSA density calculation, and PI-RADS-compliant reporting into a single platform, delivering diagnostic accuracy19 and standardization of care.19 From initial scan review to targeted biopsy handoff, the solution connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer while supporting radiologists at every step. The Suite supports customer programs in the US and was recently selected to support the TRANSFORM prostate screening trial in the UK. 
AI Studio — Enabling a Sustainable and Responsible AI Ecosystem: AI Studio, developed in partnership with CARPL and RagaAI, unifies a range of ecosystem AI solutions and enables seamless orchestration of these applications directly within the clinical workflow for automation and AI-powered care. AI Studio can integrate 140+ AI algorithms from 75+ ecosystem vendors, along DeepHealth’s own clinical AI solutions, directly into the worklist, viewer, reporting and workflow engine. The system includes governance tools for AI evaluation, monitoring and drift management in production, ensuring consistent performance and safe, reliable deployment at scale. 
At the core of this portfolio is DeepHealth OS™, a cloud-native operating system that brings together these imaging informatics and AI suites into one unified environment. The OS delivers personalized, role-based experiences with seamless access to clinical and operational data, meeting the needs of every participant in the imaging workflow. With all solutions running on one cloud-native or hybrid platform, deployment, operations, security and infrastructure management are greatly simplified for IT professionals implementing tech solutions in healthcare. 

DeepHealth works with leading OEMs, cloud, AI, and platform partners to unify previously fragmented tools into a connected, end-to-end imaging experience. Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 2,000 customers and more than 5,000 radiologists leveraging its current solutions to deliver better care. 

DeepHealth’s portfolio20 is presented in scientific sessions and at Booth #1329, South Hall, Level 3 at McCormick Place in Chicago. Anchoring the space will be an Experience Theater where visitors can experience interactive, hands-on educational lectures illustrating how AI is being integrated into practice across diverse clinical and operational areas. The Theater will also feature live sessions and panel discussions with clinical collaborators, technology partners and research leaders sharing insights from real-world AI deployments and upcoming technological advancements. 

Explore more about DeepHealth’s presence at RSNA 2025 and view the full schedule of live Experience Theater sessions at deephealth.com/rsna. 

About DeepHealth 
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, prostate, neuro, and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com 

About RadNet, Inc. 
RadNet, Inc. is a leading provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has about 11,000 team members. https://radnet.com

Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the unifying clinical and operational intelligence into one system and enabling rapid-scale infrastructure that accelerates adoption, our technology becomes a catalyst to stage shift disease, expand patient access, elevate care teams and enhance operational efficiency, discussions regarding our product feature, and statements regarding our recent acquisitions. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts 
Jane Mazur 
SVP, Corporate Communications
+1 585-355-5978 
[email protected] 

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References 

Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components. Data on file. In a pilot deployment at 64 locations inside of RadNet’s New York area facilities, TechLive™ significantly contributed to a 27% increase in advanced breast MRI as a result of using DeepHealth’s TechLive remote scanning capability across 33 MR systems at RadNet NY centers since Feb 2025. Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Risk Assessment is not cleared for use in the U.S. BAC is in development; regulatory submission planned prior to the end of 2025. Not cleared for use in the US. Not all products and functions are available in all markets. Any claims made about Breast Suite may reference claims associated with its individual components.Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025. McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025. Not cleared for use in the U.S. Capability available in Europe. In development, regulatory submission planned prior to the end of 2025. Not cleared for use in the US. DeepHealth Thyroid Suite comprises multiple applications including DeepHealth Viewer and DeepHealth Thyroid AI. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth. DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and Distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.Data on file. Summary of Performance Testing Studies, Thyroid 510(k) clearance. Data on file. “Evaluation of AI-enhanced Thyroid Ultrasound Reporting Software for Improved Diagnostic Consistency.”Data on file. DeepHealth’s Thyroid AI demonstrated up to a 30% reduction in scan slot time. Initial deployment at RadNet outpatient imaging centers.Data on file. Results are based on data from 240+ RadNet sites and 22,000 thyroid studies.Neuro Suite comprises multiple applications including Brain Health, Brain Age and DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD and distributed by DeepHealth. Any claims made about Neuro Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.Chest Suite comprises multiple applications including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng. Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc. Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the US. HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc. DeepHealth Lung AI is 510(k) pending. Not all products and functions are available in all markets.Identifies solid and sub-solid nodules (3-30mm) with 91% sensitivity, 1 false positive per scan. Setio et al. “Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules….” Med Image Anal. Dec 2017. Increases agreement (κ up to 0.82), reduces reading time up to 42%. Hempel et al. “Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules o….” Eur J RadiolOpen. Aug 2022. Mouland et al. “Targeted Lung Health Check Programme Final evaluation report.” Ipsos. November 2024.DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending. Any claims made about Prostate Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.Data on file. DeepHealth pivotal study for FDA 510(k) clearance of Prostate AI, 12-reader by 250-case MRMC study and standalone testing on the same 250 exams.Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact a DeepHealth representative.

SummaryMSCI stands out as a premier fund operator benefiting from the explosive growth in ETFs and passive investing trends.MSCI's recurring revenue, robust margins, and double-digit EPS growth support its fair value estimate of $641, offering a 9% upside from current levels.Risks include client concentration, notably with BlackRock, and potential pressure on asset-based fees. But MSCI's financial stability and dividend growth mitigate concerns.Combining MSCI's low-yield, high-growth profile with higher-yielding investments can optimize dividend portfolios for both growth and income potential.Black Friday Sale 2025: Get 20% Off ismagilov/iStock via Getty Images

Co-authored with Kody's Dividends

The stock market is an interesting beast to watch.

Many people view the stock market as one holistic thing, often referring to it as "Mr. Market." Yet we have to understand that the stock market is not a singular entity

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kody is long BLK

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The monthly XRP chart has entered one of its most decisive phases in years, and one of the asset’s most vocal analysts is laying out a blunt roadmap. Egrag Crypto, known for his long-standing bullish stance on XRP, released a new technical update that breaks down the future outlook for the cryptocurrency into three straightforward outcomes. 

The chart accompanying his analysis shows XRP trading around the $2.20 region, sitting just above an important Fib support level but still wrestling with momentum, with the monthly candle about to close.

XRP Must Close Above $2.60 To Keep Bullish Momentum Intact
Egrag’s first decisive level is at $2.60, which matches with the 0.5 Fibonacci retracement level on the monthly chart. The analyst described a close above this region as bullish but the asset would not yet be fully clear of danger. The chart shows XRP repeatedly testing this price level in the first half of the year before breaking above it in July. However, the most recent breakdown in Q2 2025 has now put the price level in focus again.

The analysis becomes more aggressive once price action breaks above $3.40. EGRAG identified this as the 0.888 Fibonacci level, one of the final retracement zones.

According to him, a close above this level confirms a super-bullish macro breakout, which he summarized with the phrase “we are so back.” The chart reinforces this idea by showing a tight compression beneath this upper 0.888 Fib cluster, and that a decisive breakout could lead to a rapid move into new all-time high prices if there’s enough buying pressure.

XRP Price Chart. Source: @egragcrypto On X 

A Close Below 21 EMA Would Break Bullish Structure
The downside scenario in Egrag’s breakdown is equally straightforward. He warned that a close below the 21-month EMA would mean a severe failure of the bullish trend structure. His wording was intentionally harsh, noting that such a breakdown would mean “we are f**ked, no sugar-coating it.”

XRPUSD currently trading at $2.19. Chart: TradingView
The chart shows the 21 EMA currently sitting around the $1.83-$1.90 price zone, forming the final major support on the monthly timeframe. Losing this level would drag XRP back into a deeper corrective zone and finally undo most of the price advancement made this year.

A significant development showed up towards the end of the week that aligns with the bullish continuation Egrag outlined. 21Shares confirmed that its US Spot XRP ETF, which is listed under the ticker TOXR, has received SEC approval and will officially launch on Monday.

The upcoming launch adds a perspective that institutional participation in XRP is only beginning. If inflows follow the early strength seen from other issuers, the ETFs could reinforce the bullish case Egrag mapped on the chart, especially if the XRP price is able to cross above $2.60 in December.

Featured image from Pixabay, chart from TradingView

XRP price targets $3 following 8% weekly gain. Institutional demand surges with $666.6M ETF inflows while large holders add $330M in tokens.

Newton Gitonga2 min read

30 November 2025, 10:32 AM

Source: ShutterstockAt the time of this writing, XRP is trading at around $2.19, indicating a 0.44% gain in the last 24 hours and a 7.28% gain over the week. The cryptocurrency held a strong market structure following several days of price consolidation.

XRP price chart, Source: CoinMarketCap

Technical indicators pointed toward continued strength in the near term. Market analysts noted that XRP's ability to defend the $2.00 support level demonstrated solid underlying demand. The broader cryptocurrency market showed signs of recovery, with Bitcoin trading at around $91,326 and Ethereum $3,007 at press time.

Institutional Capital Flows Into XRP ProductsETF inflows reached approximately $666.6 million in November within just two weeks of launch. The 21Shares U.S. spot XRP ETF will begin trading on Monday under the ticker symbol TOXR. This marked a significant milestone for institutional access to the digital asset.

Major financial firms backed their XRP ETF offerings. Grayscale and Franklin Templeton both supported products tracking the cryptocurrency's performance. The seven-day period saw XRP climb 16% as institutional participation accelerated.

Large holders increased their positions substantially. Wallets containing over one billion XRP added approximately 150 million tokens since November 25. At current prices, this represented roughly $330 million in new capital allocation. The whale accumulation suggested confidence among sophisticated investors.

Technical Setup Points to Higher PricesThe current price structure remained constructive for bulls. XRP traded firmly above the critical $2.00 support zone, which buyers defended throughout recent sessions. This level served as a foundation for the next potential leg higher.

The MACD indicator showed narrowing lines near the centerline. This pattern typically preceded increased volatility in either direction. However, the price action suggested upward movement remained more likely given recent momentum.

The Relative Strength Index registered around 52, indicating balanced market conditions. This mid-range reading left substantial room for appreciation before reaching overbought territory. Traders viewed this as favorable for sustained gains.

Price targets came into focus as momentum built. The immediate resistance sat at $2.40, followed by $2.60 as the next key level. A break above these zones could open the path toward the psychologically important $3.00 mark.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

XRP (Ripple) News

Sun, 30/11/2025 - 10:40

XRP might not show anything impressive at this point in time, but the dynamic on the derivatives market is certainly creating a basis for a reversal.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

One of XRP’s most obvious contrarian signals in weeks was just printed. The market is severely short-loaded, which is why the funding rate, currently close to 0.0022%, is strongly skewed toward the bullish side, not because traders are excessively ecstatic.

XRP's funding battleWhen funding remains this low, the open interest structure is usually dominated by shorts, and long positions are paying very little to maintain their trades. Put simply, there is a huge shortage of XRP, and there is very little risk associated with betting against them. When sellers lose momentum, that setup has historically been a sign of abrupt upside reversals.

XRP/USDT Chart by TradingViewThe chart also shows the pressure. Although XRP is still trading inside a declining channel, buyers are beginning to reenter the market based on the recent bounce from the lower boundary. Rising long, short ratios on Binance and OKX coincide with that rebound, indicating that traders are beginning to position for a countermove.

HOT Stories

What's up with XRP liquidity?The liquidity metrics also show something more meaningful: after weeks of losses, capital is moving back to the long side due to multi-time-frame net inflows into futures positions. Although there are still mixed flows in the spot market, the positive net inflow over the past 30 minutes and the past hour indicates that demand is gradually increasing.

You Might Also Like

Price action is still far from a confirmed breakout despite this. To reverse momentum, XRP must challenge $2.30, $2.35, and the larger bearish structure would only be refuted by a break above the declining trendline.

For now, the main bullish argument is rooted in market structure rather than the chart. A heavily shorted asset with weakening selling pressure typically rises far more quickly than most traders anticipate. XRP could easily stage a swift push toward the mid-$2 zone if shorts are squeezed, and the setup is clearly leaning in that direction.

Related articles

Solana closed out another high-velocity week with a fresh wave of product launches, ecosystem wins, and institutional milestones, reinforcing its position as one of the fastest-moving networks in crypto.

Momentum began with major financial players deepening their involvement in the network. Cash App revealed plans to roll out USDC payments powered by Solana in 2026, while SoFi became the first regulated U.S. bank to offer SOL trading directly from checking accounts.

Figure also broke new ground by creating YLDS, a registered public debt security issued natively on Solana. Meanwhile, Dupe Solana, an AI-powered deal finder, surged to the No. 1 spot on the App Store. This rise is an early demonstration of how consumer-facing AI apps are finding traction on the chain.

In other news, the Solana Incubator opened applications for its fourth cohort in New York, and preparations intensified ahead of Breakpoint, now 24 days away. Hackathon participation reflected that buildup: the Cypherpunk Hackathon reached 1,567 submissions, while the x402 Hackathon surpassed 400.

New products rolled out across exchanges, wallets, infrastructure providers, games, and payment tools. OKX made all Solana tokens fully tradeable, Super Group launched South Africa’s first rand-based stablecoin, and Trust Wallet introduced gas sponsorship for swaps.

Advertisement
 

Meanwhile, Axiom Exchange enabled private trading, Unruggable_io unveiled a Solana-native hardware wallet, and Decaf released a global card for spending directly on Solana. Gaming also expanded through Racer.fun’s Solana Grand Prix and Lucky Hash’s on-chain scratchcards.

Furthermore, integrations accelerated across the ecosystem. Jupiter is linked with Robinhood, DFlow is connected to Manifest Trade, Wasabi is tied into Titan Exchange, and Pyra revealed its V3 upgrade with swaps and ROI projections.

Audius added a Kodak Black coin-gated track, Drip shipped Posts with Solana joining, and Supabase began supporting Solana as an identity provider.

Moving on, Solana projects raised $211 million in Q3 2025, a 70% quarter-over-quarter jump. NYSE also introduced options trading for BSOL and GSOL, Squads secured over $2.2 billion in stablecoins, and Helium hit record revenue and burns. Meanwhile, Holoworld AI topped daily volume on x402scan, while Fitted Closet climbed to No. 19 on the App Store.

With ecosystem activity widening on every front, Solana heads into Breakpoint with more momentum than at any point this year.

XRP Poised for Continuation as Higher-Low Structure Signals Buyer DominanceMarket analyst Trader Rai notes that XRP is flashing a powerful bullish setup, thanks to a decisive higher-low formation that signals buyers remain firmly in control and sets the stage for a potential continuation rally, so long as key support levels hold.

Source: Trader RaiXRP’s higher-low formation, paired with strong upward momentum, underscores clear buyer dominance, especially as exchange supply plunges over 45% in just 60 days. This bullish structure signals that buyers are stepping in earlier with every dip, a classic sign of growing confidence and sustained demand. 

With market sentiment turning cautious across the broader crypto landscape, XRP’s ability to maintain rising lows and accelerating momentum highlights its relative strength and a decisive shift in favor of the bulls.

Trader Rai highlights $2.20 as the decisive level that will determine whether XRP’s momentum turns into a full bullish continuation. Holding this retest zone would confirm the higher-low structure and show that buyers are confidently absorbing sell pressure, keeping firm control of the trend.

Holding above $2.20 positions XRP for a clean move toward its next major resistance levels, where the market’s reaction will reveal whether the bullish trend can sustain. 

A decisive breakout through these zones would strengthen the upward trajectory and draw in sidelined buyers waiting for confirmation. However, a drop below $2.20 could trigger short-term uncertainty, though the broader bullish structure remains intact unless a deeper breakdown unfolds.

Therefore, Trader Rai’s analysis underscores a key takeaway that XRP’s price action reflects a market steadily gaining bullish strength. Momentum, structure, and critical support levels are aligning decisively in favor of continuation. As long as buyers defend the $2.20 zone, the odds of XRP pushing into higher resistance levels remain firmly on their side.

In a market where confidence thrives on clear technical signals, XRP is displaying the disciplined bullish structure analysts expect in the early stages of a breakout. If current conditions persist, the asset appears poised for its next major leg upward—driven by buyers who show no signs of stepping back.

XRP Supply on Exchanges Plunges Over 45% in 60 Days, Signaling a Major Market ShiftMarket expert Xaif Crypto acknowledges one of XRP’s largest supply contractions in years. Glassnode data shows centralized exchange balances have plunged over 45% in just 60 days, signaling a dramatic shift in holder behavior and potential for heightened price volatility.

Source: Xaif CryptoExchange-held XRP has plummeted from 3.95 billion on September 21 to 2.6 billion by November 27, removing over 1.3 billion tokens from liquid supply. This sharp decline signals more than routine movement, it reflects a growing trend of investors moving XRP into self-custody, long-term holdings, or staking, highlighting rising confidence in the asset’s long-term value.

Xaif Crypto stipulates that the sharp drop in XRP supply on exchanges signals rising accumulation and waning sell-side pressure. Withdrawn tokens are less likely to hit the market, a pattern that often precedes bullish moves. Xaif Crypto notes that such a supply shock can ‘tip the balance entirely toward buyers,’ especially if demand picks up.

“Glassnode data shows whales and long-term holders are driving XRP accumulation, signaling a shift from speculative trading to strategic holding. 

With exchange supply down 45%, market attention is turning to volume, liquidity, and potential breakout patterns. This decline isn’t just a number, it reflects growing confidence and a market positioning itself for what could be a major move in the weeks ahead.

ConclusionNotably, XRP’s market structure signals clear bullish control. Trader Rai notes that the higher-low formation and accelerating upward momentum keep buyers in command. Holding above the $2.20 retest zone could pave the way toward higher resistance levels, with growing momentum and favorable sentiment positioning XRP for a potential breakout that may set its next major trend.

On the other hand, the 45% plunge in XRP supply on exchanges signals a decisive market shift. With more tokens moving into long-term holdings, sell-side pressure is easing, paving the way for potential bullish momentum. 

This trend reflects growing confidence in XRP’s long-term value and underscores how supply scarcity can drive price action. Monitoring exchange balances and accumulation trends will be crucial in anticipating XRP’s next major move.

Bitcoin's exponential rate of growth also comes with enormous volatility.

Investing in ultra-high-upside cryptocurrencies could be one way to maximize the value of your overall investment portfolio. Several top cryptocurrencies are now up more than 1,000% since launch, making them a potential way to 10x your net worth.

The best of these, of course, is Bitcoin (BTC +0.42%). Even with its recent pullback, it's still up 146,000,000% since launch. Even if its eye-popping rate of growth eventually cools, it could still help you to generate life-changing wealth.

Bitcoin's exponential rate of growth
Bitcoin has been growing at an exponential rate over the past 15 years. In seven of the past 13 years, Bitcoin has more than doubled in value. That includes one monster year (2013) when Bitcoin delivered returns of 5,428% to investors.

Today's Change

(

0.42

%) $

383.52

Current Price

$

91066.00

The real magic happens when this doubling in value is allowed to compound over time. For example, Bitcoin soared by 157% in 2023 before skyrocketing in value by 125% in 2024. That's a doubling on top of a doubling. At the start of 2025, the common assumption was that Bitcoin would once again double in value, fueled by all the pro-Bitcoin and pro-crypto rhetoric coming out of the new Trump administration.

Due to this exponential growth, Bitcoin has exploded in price, from $0.10 to $100,000, in a remarkably short period of time. It took Bitcoin just a few months to increase in price from $0.10 to $1, and approximately two years to increase from $1 to $10.

Image source: Getty Images.

In 2013, Bitcoin absolutely exploded in price, moving from $10 to $100 and then $1,000 in the course of just a single year. From there, it took Bitcoin four years to increase from $1,000 to $10,000, and then seven years to increase from $10,000 to $100,000.

Does Bitcoin still have 10x upside?
The good news is that Bitcoin is likely still poised for a 10x upside. The growing consensus is that Bitcoin can make the jump from $100,000 to $1 million in just five years. So, if you buy Bitcoin today and hold on for the next five years, you might see a 10x increase in the value of your Bitcoin position.

It gets even better than that, because some bullish crypto investors think Bitcoin could eventually go much higher within the next two decades. Michael Saylor, founder and executive chairman of Strategy (MSTR +0.88%), thinks Bitcoin could reach a price of $21 million within the next 21 years, based on Bitcoin's rocketing pace of institutional adoption.

There are several important catalysts with the potential to catapult Bitcoin higher over the next decade. One of these is the creation of the Strategic Bitcoin Reserve within the United States. That has ignited similar types of proposals around the world, leading to the suggestion that a Bitcoin bidding war will break out among the major sovereign nations of the world. Some have referred to this as a "Bitcoin arms race."

Caveats for potential Bitcoin investors
By now, you might be thinking: This sounds too good to be true -- no asset can double in value every year, just like clockwork.

You'd be right. Bitcoin's fatal flaw is that it is prone to enormous volatility and dramatic downturns. While its long-term direction has been straight up, it has had several notable collapses along the way. In 2014, for example, Bitcoin lost 57% of its value. In 2018, it lost 74% of its value, and in 2022, it lost 64% of its value.

Simply put, while Bitcoin has achieved several periods of exponential growth, it is not growing at a compound annual growth rate (CAGR) of 100% or higher. Instead, its CAGR for the period of 2017 to 2025 was just 50%.

But that's perfectly OK, because that's almost high enough to put Bitcoin on a glide path to $1 million by the year 2030. In order to soar from a price of $100,000 to a price of $1 million within five years, Bitcoin would need to grow at a CAGR of 58.5%.

How much should you allocate to Bitcoin?
It's easy to see how Bitcoin itself has 10x upside potential. But what about your overall investment portfolio? Does it also have 10x upside potential?

If your portfolio consists solely of Bitcoin, then the answer is "yes." But you most likely have much more in your portfolio than just Bitcoin. So you would need to make a judicious decision about how much of your portfolio to allocate to Bitcoin. Right now, a conservative asset allocation to Bitcoin is 1%, while a more aggressive allocation is 5% or higher.

The more that you allocate to Bitcoin, the faster you can potentially grow your net worth. But it also means that there's a greater risk to your portfolio entirely if Bitcoin suddenly crashes in value, as it did in 2014, 2018, and 2022.

So before you decide to invest in Bitcoin, make sure you get the asset allocation right. It could have a significant effect on the overall growth of your net worth.

The total market cap is close to $3.2 trillion again.

Bitcoin’s rather dull price actions over the weekend continue as the asset remains sideways at around $91,000, but it’s up by more than ten grand since last Friday’s multi-month low.

Most larger-cap altcoins are sluggish on a daily scale, aside from HYPE, AVAX, and ZEC – all of which have dumped hard since yesterday.

BTC Taps $91K
As mentioned above, the previous business week was quite painful for the primary cryptocurrency as it plunged below $81,000 for the first time since April. This meant that it had lost over $25,000 in just ten days.

The bulls finally stepped up at this point and defended the $80,000 support. BTC started to recover some ground and quickly bounced to $84,000 last weekend. Its more impressive gains came during the business week when it initiated a leg up to $88,000 by Wednesday.

Although that resistance held at first, the bulls managed to break through it that night, and bitcoin even jumped past $90,000 at the end of the week. Its local high came on Friday morning when it surged to just over $93,000.

However, it couldn’t keep climbing, and the subsequent rejection drove it to the $90,000-$91,000 range, where it has been situated for the past 36 hours or so. Its market cap has increased to $1.820 trillion, while its dominance over the alts stands tall above 57% on CG.

BTCUSD/30.11. Source: TradingView
Weekly Gainers
The weekly charts are quite impressive, given the rebound attempts by many altcoins. ETH and XRP are up by over 7% to $3,000 and $2.20, respectively. SOL has gained 5% and so has HYPE, even though it’s down by 6% in the past 24 hours.

XMR, XLM, AVAX, SUI, SHIB, CC, and AAVE are also well in the green weekly. ZEC trades differently than most altcoins again, but this time in a painful manner. The privacy token has plunged by over 21% since last Sunday and now sits below $450.

The total crypto market cap has added over $300 billion since last Friday’s low and is close to $3.2 trillion now.

Cryptocurrency Market Overview Weekly. Source: QuantifyCrypto

Cardano has had one of the weakest months in the market. The ADA price is down more than 31% in November, even as Bitcoin and Ethereum recovered 6–8% in the same period. Over the past seven days, the Cardano price has gained only about 1.9%, showing very little momentum.

Key supply and big money signals now point to deeper weakness unless conditions stabilize soon.

Sponsored

Supply Pressure Builds as Money Flow WeakensCardano’s recent move shows clear stress on two fronts: large money flow and coins moving across age bands.

The first signal comes from CMF (Chaikin Money Flow), which reflects the strength of big money. Between November 24 and November 28, ADA’s price reached a higher high, but CMF formed a lower high and then broke below its descending trendline, which had been in place since October 11.

The same breakdown occurred on November 2, and ADA fell by more than 20% after that move. CMF is also under zero this time, which usually means big capital is stepping back rather than flowing in.

Money Flow Weakens: TradingViewWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Sponsored

The correlation is clear. Between November 10 and November 17, the big money flow fell sharply by more than 240%, and ADA corrected by more than 36% in the same period and even in the following days.

Since ADA reacts strongly to CMF trends, this fresh breakdown signals more downside risk.

The second red flag comes from the Spent Coins Age Band, which tracks how many coins across all holding groups move on a given day.

On November 29, it dropped to a monthly low of 93.23 million ADA. But instead of stabilizing as the month ended, the value jumped to 114.66 million — a roughly 23% increase. It is now at the highest weekly level.

More ADA Moving Now: SantimentSponsored

A rise in spent coins means more supply moving, and when that happens, while money flow is weakening, pressure on the price often increases.

Both signals now align. Larger inflows are waning at the same time, and more supply is being released. Together, they create a backdrop where the ADA price struggles to hold any short-term bounce.

Key Levels Show Cardano Price Might Not Be Done Correcting YetADA has been in a clear downtrend since November 11, and the broader structure has not reversed. Trend-based extension levels indicate where the Cardano price may move if pressure persists.

Sponsored

If ADA loses the $0.386 support, the next levels appear at $0.354 and $0.302. These are the natural continuation zones for this downtrend, especially if CMF stays below zero and spent-coin activity remains high.

Cardano Price Analysis: TradingViewA recovery is still possible, but it needs a clean break above $0.438 with a full candle close. Only then can ADA attempt a move back toward $0.607, but that requires two conditions to flip:

CMF must return to above zero, and the spent-coin reading must cool off again. Historically, whenever the Spent Coins Age Band spikes, ADA has struggled to sustain any recovery. The current rise reinforces that risk.

Currently, the Cardano price is trading near $0.419 and shows no signs of a reversal. Without improvements in money flow and supply movement, the 31% monthly drop may not be the final leg of this correction.

Welcome to Latam Insights, a compilation of the most relevant crypto news from Latin America over the past week. In this week's edition, Bolivia announces the integration of stablecoins into its banking system, Tether abandons mining operations in Uruguay, and the Libra Trust emerges out of the blue.

Ripple executive Luke Judges defends his Solana background, urging XRP to learn from competitors as the blockchain advances smart contracts and DeFi capabilities.

TLDR:

Bitcoin consolidates near $91K after 6% weekly gain with no clear trend confirmation yet
Price must reclaim $96K to $99K resistance zone to signal genuine bullish momentum returning
Liquidation clusters stack between $86K support and $94K resistance across derivatives markets
Weekly low remains critical threshold; break below opens path toward $70K to $66K targets

Bitcoin trades at $91,268 after a 6% weekly gain, but market structure suggests the recent bounce may be technical rather than trend confirmation. 

The cryptocurrency climbed 0.75% in 24 hours with trading volume reaching $39 billion. Price action remains trapped between critical support and resistance levels. Traders now watch whether Bitcoin can reclaim higher ground or test deeper support zones.

Technical Setup Points to Consolidation Zone
The current market structure shows Bitcoin stuck in a compressed range without clear directional intent. 

Price needs to break above $96,000 to $99,000 to signal genuine strength returning to the market. Below that threshold, the recent bounce appears to be a standard rebound following an extreme move lower.

The three-day chart reveals no meaningful accumulation patterns yet. 

BTC price bounced from a key zone that was expected to generate a reaction based on historical support levels. That bounce fulfilled its technical purpose without necessarily indicating a trend reversal.

Market observer EliZ noted the weekly timeframe remains the most important chart to monitor for true directional signals. 

$BTC macro view

Looking at both the 3D and the weekly, it’s obvious why the market bounced exactly where it did. That zone was meant to react, and it reacted perfectly. But a bounce doesn’t mean the trend is back this is just a technical rebound after an extreme move, nothing… pic.twitter.com/U7GUnO2D8f

— EliZ (@eliz883) November 30, 2025

The weekly low represents a critical line that must hold to maintain current market equilibrium. A break below that level could open the door to a move toward $70,000 to $66,000.

Volume indicators show no clear divergence or accumulation signal at current levels. 

The lack of decisive volume participation suggests BTC sits in an indecision phase rather than forming a confirmed bottom. This environment often traps traders who call bottoms prematurely without waiting for structural confirmation.

Liquidation Data Shows Packed Zones Above and Below
Liquidation heatmap data from CoinAnk reveals concentrated clusters at key price levels over the past 24 hours. 

Short-term support sits between $86,800 and $88,000, where overleveraged long positions remain vulnerable. These zones could fuel sharp bounces if tested through forced buybacks and short-covering activity.

Resistance bands between $94,000 and $94,650 contain heavy short position liquidations from recent rally attempts. 

A decisive break above this range could trigger an aggressive short squeeze. Rejection at these levels risks unleashing cascading long liquidations back toward support.

Source: CoinAnk/X
Total liquidation volume registered around $93 million over the 24-hour period. This relatively contained leveraged activity shows horizontal stacking patterns in the heatmap.

The market remains coiled and highly reactive to tests of these densely populated price magnets.

The current setup represents a transitional zone where Bitcoin cleans liquidity, traps impatient traders, and prepares for its next major move. The $96,000 to $99,000 resistance will determine if strength returns. 

The weekly low will signal whether much deeper support levels come into play. Everything between these boundaries represents noise rather than actionable trend signals.

Bitcoin (BTC) failed to reclaim $93,000 despite positive momentum in the US stock market and rising gold prices. With the S&P 500 trading just 1% below its all-time high, traders are evaluating what could spark sustainable bullish momentum for Bitcoin.

Key takeaways:

Demand for BTC put (sell) options and stagnant ETF inflows kept momentum capped despite easing macroeconomic conditions.

AI-driven tech relief has cut market stress, but BTC strength relies on holding $90k as investors bet on liquidity support amid softer job market data.

Fed target rate expectations for Dec. 10. Source: CME Group FedWatch ToolBond market futures data from CME Group shows traders assigning 87% odds to an interest rate cut on Dec. 10, up from 71% the prior week.

Signs of weakness US the US job market prompted investors to expect a more expansionary monetary policy. The US Labor Department noted that continuing claims climbed to 1.96 million in the week ending Nov. 15.

Meanwhile, the sentiment in BTC derivatives was not significantly altered by the recent price weakness, yet demand for bullish positioning remains notably cautious.

Bitcoin futures annualized basis rate. Source: Laevitas.chBitcoin monthly futures held a 4% premium over spot markets on Saturday, unchanged from the previous week.

Under neutral conditions, this basis typically ranges from 5% to 10% to reflect carrying costs. The lack of appetite for leveraged long positions may indicate lingering concerns after Bitcoin’s 18% pullback over the past 30 days.

BTC options markets can help evaluate whether whales and market makers fear additional downside. Bearish phases are often marked by increased demand for put (sell) options.

Bitcoin options put-to-call premium volumes at Deribit, USD. Source: laevitas.chVolumes on put options far exceeded call (buy) instruments on Thursday and Friday, signaling elevated uncertainty. A more neutral market would require put-to-call premium volumes at 1.3x or below. While still well off the 5x peak level favoring downside protection seen on Nov. 21, overall sentiment in Bitcoin derivatives remains cautious.

Part of this hesitation stems from stagnant flows into Bitcoin exchange-traded funds (ETF), which added only $70 million in net assets during the week ending Nov. 28.

Additionally, none of the companies that use Bitcoin as a primary reserve asset have expanded their holdings over the past two weeks, according to CoinGlass data.

Top companies holding BTC reserves. Source: CoinGlassStrategy last added Bitcoin on Nov. 17. More concerningly, holdings attributed to SpaceX moved 1,163 BTC to two new addresses on Thursday, fueling speculation about a potential sale.

🚨 NEW: SpaceX moves 1,163 $BTC worth about $102M to two new addresses, per Nansen data. pic.twitter.com/KnV5qJSeaI

— Cointelegraph (@Cointelegraph) November 27, 2025It remains unclear whether Elon Musk’s privately held aerospace company changed custodians, as no official statements have been issued.

Trump’s tax-cut plans boosted scarce assetsDuring the US holiday, President Donald Trump reiterated plans to substantially cut income taxes, citing revenue expected from import tariffs.

Investors grew more willing to take risks as it became clear that government debt would remain under heavy upward pressure, a backdrop typically supportive of scarce assets. Gold gained 3.8% during the week, while silver surged to a new all-time high.

Concerns around the artificial intelligence sector eased after Google’s custom TPU chip enabled Gemini to top benchmarks in coding, math, science and multimodal reasoning.

The breakthrough boosted investor confidence, as the technology uses far less energy than GPU-based processing. Alphabet (GOOG US) gained 6.8% on the week, helping reduce fears about Nvidia’s (NVDA US) growth outlook.

S&P 500 Index (left) vs. Bitcoin/USD (right). Source: TradingView / CointelegraphBitcoin’s path to $100,000 appears increasingly independent of broad macro trends, however, as its correlation with tech stocks continues to fade.

The longer BTC holds above $90,000, the more confident bulls become, supported by the return of ETF inflows, less risk aversion in BTC derivatives, and the likelihood of liquidity injections from the central bank.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

The used-car retailer will update investors next month about its turnaround and CEO search.

CarMax (KMX +1.20%) is heading into its Dec. 18 earnings report facing the toughest backdrop in its 32-year history.

The stock has collapsed more than 50% year to date, slumping to a 13-year low after a brutal second-quarter miss on sales and earnings per share (EPS). It's now down 75% from its November 2021 all-time high -- one of the deepest multiyear slumps of any major specialty retailer.

With a market cap of $5.5 billion, CarMax is now the second-smallest of 44 stocks in the Consumer Discretionary Sector SPDR Fund (XLY +0.62%), which tracks the consumer discretionary sector. That market segment has been among the worst performing sectors this year.

Today's Change

(

1.20

%) $

0.46

Current Price

$

38.66

With CarMax currently operating under an interim CEO and interim executive chairman following the sudden removal of former CEO Bill Nash in September, its upcoming Q3 results will serve as a reboot for expectations and outlooks on how the country's largest used car retailer plans to regain traction and upward trajectory.

With that backdrop, investors need to keep two key forces in mind for the time being.

Image source: Getty Images.

1. Affordability
While used car prices have come down from record highs set in 2022, the average is still close to $26,000, a reality CarMax noted has seen customers shift toward older, higher-mileage vehicles. At the same time, interest rates have come down but are still elevated, with CarMax's finance arm reporting an average rate of 11.2% in Q2 -- a level that also pressures affordability, and in turn, wholesale buying and selling.

These macroeconomic pressures, along with tariff-related demand shifts earlier this year, were also highlighted in the specialty retailer's latest results -- mirroring similar stress reported throughout the sector.

In its favor, however, by almost any valuation metric, shares of CarMax have never been cheaper. According to Koyfin data, its trailing-12-month price-to-earnings (11.2), price-to-sales (0.2), and price-to-book (0.9) ratios have never been lower during the past 20 years.

2. CEO shake-up
The board's decision to remove its long-tenured CEO following the Q2 earnings release has only underscored the urgency of the situation. Interim CEO David McCreight and interim Executive Chair Tom Folliard are now tasked with stabilizing the business while also reassuring investors that CarMax's omnichannel model, online appraisal engine, and finance arm can adapt to changing consumer preferences and reaccelerate when affordability normalizes.

"The Board has decided that more direct involvement from David and me will help strengthen the business in this transitional period," Folliard said in the Nov. 6 statement, adding, "we are focused on driving sales, enhancing profitability and reducing cost."

Analysts are, unsurprisingly, cautious though not outright bearish, with 14 hold ratings and two buy ratings. Their average 12-month price target, however, has been halved from $81 in early September to $40 today, which implies about 7% upside from recent levels.

Conclusion
CarMax is now a deep-value turnaround story that's sitting at the intersection of a tough affordability cycle and a sudden leadership reset. But if pricing continues to normalize and interest rates trend lower, the stock's historically low valuation could set the stage for a rebound.

Until then, management needs to prove it can stabilize the company and deliver fresh catalysts to encourage investors to revisit its stock.

This semiconductor specialist is a strong contender in the artificial intelligence (AI) race.

Since the dawn of artificial intelligence (AI), the companies at the forefront of this groundbreaking technology have generated impressive gains for shareholders. Chief among these have been the so-called "Magnificent Seven" stocks.

The group is made up of some of the world's most recognizable companies, including Nvidia, Meta Platforms, Alphabet, Tesla, Amazon, Apple, and Microsoft. Each of these companies is an industry leader, and every member of the collective has delivered stock price gains of 100% or more since early 2023.

However, those who focused solely on these AI bellwethers have likely missed out on one of the crucial players in the AI boom. In fact, investors might be surprised to find that Broadcom (AVGO +1.37%) stock has outperformed every member of the Magnificent Seven over the past year, surging 142%, and is poised to move higher. I would submit that the semiconductor and data center specialist has the momentum to join the $3 trillion club by 2027.

Image source: Getty Images.

Chips ahoy!
The rapid and ongoing expansion of data centers has been central to the accelerating adoption of AI. While Broadcom made a name for itself in the semiconductor industry, the company is also a key supplier of the networking components and accessories that are essential to data center operations, in addition to its product offerings in the broadband, cable, and mobile sectors. Broadcom boasts that "99% of all internet traffic crosses through some type of Broadcom technology." This puts the company in the position to supply critical components for the ongoing data center buildout required to support AI.

Perhaps the most important of these are Broadcom's Application-Specific Integrated Circuits (ASICs), which are semiconductors that can be customized for specific use cases. Just last month, Broadcom announced a multibillion-dollar deal with ChatGPT creator OpenAI to supply 10 gigawatts of these specialized chips over the coming four years.

Broadcom's ASICs are expected to help OpenAI improve speed while also being more energy efficient. This deal established Broadcom's ASICs as a viable alternative to Nvidia's industry-leading graphics processing units (GPUs), which currently control a dominant 92% share of the data center GPU market.

Broadcom's financial results reveal the impact. In the third quarter, Broadcom generated record revenue, climbing 22% year over year to $15.9 billion, which fueled adjusted earnings per share (EPS) of $1.69, a 36% increase.

Broadcom believes its AI opportunity will rise to between $60 billion and $90 billion by 2027 for its three existing hyperscale customers. During the earnings call, CEO Hock Tan said one of the company's major prospects -- which we now know was OpenAI -- had approved a production order for its ASICs. The deal is expected to generate $10 billion in additional revenue next year. Broadcom is also "deeply engaged" with other hyperscalers for its custom AI chips, which could fuel the company's next leg higher.

Today's Change

(

1.37

%) $

5.43

Current Price

$

403.00

The path to $3 trillion
Given its crucial role in the data center space and its GPU-alternative processors, Broadcom is well positioned to profit from the continuing AI boom.

Broadcom is expected to generate revenue of $63.3 billion in 2025, according to Wall Street estimates, giving it a forward price-to-sales (P/S) ratio of roughly 29. If the stock's P/S remains constant, Broadcom will need to generate revenue of roughly $101 billion annually to support a $3 trillion market cap.

Wall Street's expectations are bullish, guiding for revenue growth of 29% annually over the coming five years. If the company hits those targets, it could surpass $100 billion in revenue and achieve a $3 trillion market cap as early as 2027. Given the company's accelerating results in recent quarters and that it's courting new hyperscale customers, this timeline could be conservative.

Nvidia CEO Jensen Huang has gone on record saying that data center spending will rise to between $3 trillion and $4 trillion over the coming five years. This represents a significant opportunity for Broadcom, as its ASICs are viewed as a viable alternative to GPUs, particularly when energy efficiency is a key consideration. If the company can carve out just a portion of Nvidia's market share -- and I have no doubt that it can -- the sky's the limit for Broadcom.

Despite the recent surge in its stock price, Broadcom still sells for less than 32 times next year's expected earnings. Furthermore, it sports a price/earnings-to-growth (PEG) ratio of 0.42, when any number less than 1 is the hallmark of an undervalued stock.

That's why I believe Broadcom stock is a buy and on its way to membership in the $3 trillion club.

Danny Vena, CPA has positions in Alphabet, Amazon, Apple, Broadcom, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Stanley Druckenmiller is considered one of the greatest investors of all time.

When you look at most hedge funds these days, their portfolios are littered with artificial intelligence (AI) stocks. After all, AI has driven the market higher for the past three years.

While billionaire Stanley Druckenmiller owns plenty of AI and tech stocks, his fund's top three holdings lie in the biotech sector. The sector can be challenging for most retail investors without a science background to invest in, and it's also highly speculative. But Druckenmiller is undoubtedly one of the best to ever do it.

The George Soros protege has generated legendary returns for decades, so it's hard not to take stock in where Druckenmiller is investing. Three biotech stocks in his private investment firm, Duquesne Family Office, make up 30% of the entire portfolio.

Image source: Getty Images.

Natera -- 13%
Duquesne owned over 3.2 million shares of Natera (NTRA +0.71%) valued at over $517 million at the end of the third quarter. While not an AI company, Natera leverages artificial intelligence to try and discover diseases and conditions in humans earlier in their life cycles. The earlier a person becomes aware of a condition, the more likely they are to be able to address it effectively.

Natera currently focuses much of its efforts on women's health issues, oncology, and organ health. The company's state-of-the-art tech platform looks for circulating cell-free DNA (cfDNA); it can detect a single molecule in a tube of blood by pairing new biology practices with bioinformatics. The platform is used to administer a noninvasive test for pregnancy detection, as well as the first blood test to detect tumor-specific DNA, among other groundbreaking tools.

Natera has performed well, with the stock up 48% this year as of Nov. 25. The company has increased testing on several of its products and grown revenue 35% through the first nine months of 2025, compared to the same time last year. Losses have also increased due to high research and development, as well as administrative expenses. Management raised annual revenue guidance for 2025 by $160 million. While the stock is expensive at close to 15 times forward revenue, the company is working on game-changing molecular testing, so right now I'd classify this one as a more speculative play with big reward potential.

Insmed -- 8.6%
At the end of the third quarter, Duquesne owned over 2.4 million shares of Insmed (INSM +1.59%) valued at roughly $349 million. Insmed is a global pharmaceutical company dedicated to developing and commercializing a range of drugs and treatments. Currently, two of its drugs have reached commercialization, with several others in the pipeline.

Arikayce is an antibiotic for the treatment of Mycobacterium avium complex (MAC), a chronic lung disease that in some cases can prove fatal, although there are both mild and harder-to-treat types of MAC. Insmed's other commercial drug is Brinsupri, the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for non-cystic fibrosis bronchiectasis (another chronic lung condition) in people age 12 and above.

The stock has done incredibly well, and is up nearly 200% year to date. Part of that is due to Arikayce's 21% revenue growth so far this year. The FDA also approved Brinsupri, which is now generating revenue. The company has a solid track record, and other drugs in the pipeline starting to move through clinical trials. If you're interested in buying shares, understand that investing in biotech stocks typically requires conducting due diligence on pending drugs and how likely they are to achieve commercialization.

Teva Pharmaceutical -- 8.3%
Druckenmiller's third-largest position is Teva Pharmaceutical Industries (TEVA +2.09%). Duquesne owned approximately 16.6 million shares, valued at roughly $335.2 million, at the end of the third quarter. Teva manufactures a wide array of commonly used drugs; these include Austedo for neurodegenerative and movement disorders typically found in people with Huntington's disease, as well as Ajovy to treat adult migraines, and many other drug treatments for cancer, asthma, and chronic obstructive pulmonary disease (COPD).

The stock has performed solidly; it's up more than 17% this year. In the third quarter, Teva grew total revenue by approximately 3% year over year to nearly $4.5 billion. The company has also swung profitable on a GAAP (generally accepted accounting principles) basis, and has grown earnings on an adjusted (non-GAAP) basis.

Teva also has a robust pipeline of drugs nearing commercialization. Two drugs it's working on to treat schizophrenia and ulcerative colitis reached phase 3 clinical trials, while one of its drugs for multiple system atrophy (MSA) received an FDA "fast track" designation.

The stock appears reasonably valued, trading at 1.7 times forward revenue and approximately 9.5 times forward earnings. Revenue isn't showing extreme growth right now, but earnings are moving higher, and the commercialization of new drugs should help on both fronts. This may be a safer biotech stock to buy right now.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NGG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment.
Short-term trading, options trading/investment and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved.
I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about.
Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.